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Background: We aim to investigate the guideline adherence of β-blocker (BB) initiating
dose in Chinese hospitalized patients with heart failure with reduced ejection fraction
(HFrEF) and whether the adherence affected the in-hospital outcomes.
Methods: This was a retrospective study of patients hospitalized with HFrEF who had
initiated BBs during their hospitalization. We defined adherence to clinical practice
guidelines as initiating BB with standard dose and non-adherence to guidelines if
otherwise, and examined the association between adherence to guidelines and in-
hospital BB-related adverse events. Subgroup analyses based on sex, age, coronary
heart disease, and hypertension were performed.
Results: Among 1,104 patients with HFrEF initiating BBs during hospitalization (median
length of hospitalization, 12 days), 304 (27.5%) patients received BB with non-adherent
initiating dose. This non-adherence was related to a higher risk (hazard ratio [95%
confidence interval]) of BB dose reduction or withdrawal (1.78 [1.42 to 2.22], P <
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hypotension, cardiogenic shock requiring intravenous inotropes, and severe
bronchospasm requiring intravenous steroid during hospitalization.
Conclusion: This study identified that over a fourth of patients had received BBs with an
initiating dose that was not adherent to guidelines in Chinese hospitalized patients with
HFrEF, and this non-adherence was associated with BB dose reduction or withdrawal
during hospitalization.
Keywords: inverse probability weighting, heart failure, heart failure with reduced ejection fraction, hospitalization,
beta blocker, adverse events < patient safety, guideline adherence [MeSH term], electronic medical records
HIGHLIGHTS
What is Already Known About This Subject?
• Current treatment guidelines recommend a “start low, go
slow” strategy when initiating β-blocker (BB) treatment for
patients with heart failure with reduced ejection fraction
(HFrEF).
What Does This Study Add?
• A fourth of patients were initiated on a starting dose of BB
that was not adherent to the guideline recommendation
among Chinese hospitalized patients with HFrEF during
hospitalization.
• Initiating BB with a higher dose was associated with dose
reduction or withdrawal of the BB treatment.
• Guideline-recommended initiating dose of BB may fit the
hospitalized scenario in patients with HFrEF.
INTRODUCTION
Heart failure (HF) is a major and growing public health problem
worldwide including in China (Liu et al., 2014; Bozkurt et al.,
2021). The aging population and improved survival from
myocardial infarction have led to the continued increase in
HF prevalence in divisions of cardiology and internal
medicine, as well as the resulting high burden of
hospitalizations and health care costs among individuals with
HF (Ziaeian and Fonarow, 2016). HF with reduced ejection
fraction (HFrEF), which is defined as left ventricular ejection
factor (LVEF) <40%, approximately accounts for 50% of cases
with HF (Maggioni et al., 2013; Murphy et al., 2020).
In the past 3 decades, dramatic advances have been made in
the understanding of the pathophysiology of HF and the
development of pharmacologic therapies that improve
functional status and reduce hospitalizations and mortality for
patients with HFrEF. These advances have led to guideline
recommendations for the use of beta-blockers (BB),
angiotensin-converting enzyme inhibitors (ACEI), or
angiotensin receptor blockers (ARB), and mineralocorticoid
receptor antagonists (MRA) in patients with symptomatic
HFrEF (Teng et al., 2018).
Increasing evidence shows that insidious symptoms may be
overlooked in people with early-stage HF in primary care until
the emergency room visit due to acute exacerbation of the HF
condition (Bottle et al., 2018). The majority of patients with
HFrEF may therefore receive their first BB dose during their
hospital stay rather than in the community setting following
discharge (Smeets et al., 2016; Bottle et al., 2018). For these
patients with incident HF hospitalization, the prescribing of HF
medications at discharge including BBs has been used as an
indicator of the quality of care (Gattis et al., 2004; Fonarow et al.,
2007). It is, however, noteworthy that BB could be initiated at the
time of presentation with an episode of acute decompensated HF.
Current clinical practice guidelines (CPGs) recommend a
“start low, go slow” strategy of BB treatment, suggesting that
BBs be started at low doses, not more than 1/8 of the target dose,
and are slowly uptitrated over weeks or months (Chinese Society
of Cardiology of Chinese Medical Association, 2014; Ponikowski
et al., 2016). However, many clinicians argue for a higher starting
dose of BB during hospitalization to avoid delay or possibly
failure to uptitrate the BBs after discharge due to unfamiliar use of
BBs in HF among general practitioners (GPs) in the community
(Fuat et al., 2003; Hancock et al., 2014; Smeets et al., 2016). Many
GPs continue to consider the initiation of BBs to be in the critical
care pathway in the hospital (Ansari et al., 2003; Ventura, 2004;
Bhatt et al., 2017).
Nevertheless, it is unclear what the practice of Chinese
clinicians with initiating doses of BBs in patients with HFrEF
in the real-world hospital setting is. The consequence of non-
adherence to CPG recommendations is not known. We have
conducted a population-based study to evaluate the proportion of
patients who had been initiated on a starting dose of BBs that was
non-adherent to CPG recommendations and explore the impact
of non-adherence to CPG on acute BB-related adverse events.
METHODS
Study Population
This study retrospectively recruited Chinese patients with HFrEF
using electronic medical records (EMRs) from the West China
Hospital of Sichuan University (Zhou et al., 2021a) who 1) were
discharged between January 1, 2011 and September 30, 2018; 2)
were ≥18 years old; 3) had an LVEF <40% (echocardiography
reading); 4) had a length of stay >2 days; 5) initiated BBs during
hospitalization (did not receive BBs within the two calendar days
after admission but a new BB on the third calendar day or later);
and 6) had essential records of laboratory tests [serum creatinine,
N-terminal pro-B type natriuretic peptide (NT-proBNP), low-
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density lipoprotein (LDL-C), hemoglobin and cardiac troponin T
(cTNT)] and vital signs [heart rate, and systolic and diastolic
blood pressures (BPs)]. We excluded patients underwent any
non-interventional surgery.
This study was approved by the ethical committee of West
China Hospital, Sichuan University (No. 2019-472). The patient
consent was waived for data collection of this study was based on
the EMR system retrospectively.
Data Collection
We collected the information of age, sex, smoking, alcohol
consumption, surgery, prescription, admission department,
discharging diagnoses with International Classification of
Diseases, 10th Revision (ICD-10 codes), and patient status on
discharge in the EMR system for each patient. We also extracted
vital signs (systolic and diastolic BPs, heart rate, and respiration
rate), height, and weight from the nursing system, laboratory test
results from the laboratory information system (LIS), and LVEF
from the echocardiography reading. For patients admitted more
than once, we collected the data derived from their first
hospitalization. Body mass index (BMI) was calculated as
weight (kg) divided by height (m) squared. We used records
of prescriptions within the two calendar days after admission, the
first record of each vital sign, the first laboratory test results
during hospitalization as baseline characteristics for each patient.
The estimated glomerular rate filtration (eGFR) was calculated
according to the chronic kidney disease epidemiology
collaboration formula (Levey et al., 2009; De Cosmo et al.,
2016) using age, sex, and serum creatinine values.
Hypertension, diabetes mellitus, coronary heart disease (CHD),
arrhythmia, cardiomyopathy, rheumatic heart disease, and acute
myocardial infarction were identified using the discharging ICD-
10 codes I10 to I15, E10 to E14, I20 to I25, I44 to I49, I42, I01 to
I09, and I21 to I23, respectively. We calculated the Charlson
comorbidity index (CCI) using the ICD-10 codes of discharging
diagnoses (Charlson et al., 1987; Fraccaro et al., 2016).
Initiating Dose of BBs
A standardized initiating dose for each patient was calculated as
his/her original initiating dose recorded in the EMR divided by
the BB target dose. Recent CPGs recommend that BBs should be
initiated at a dose of no more than 1/8 of the target dose (Chinese
Society of Cardiology of Chinese Medical Association, 2014;
Ponikowski et al., 2016). Patients were identified to be non-
adherent to the CPG if they had a standardized initiating dose >1/
8, and otherwise in the adherence group.
Outcomes and Follow up
Time to event outcomes included profound bradycardia (defined
as the first episode of heart rate <50 beats per minute during BB
administration), hypotension (defined as the first episode of
systolic BP <90 mmHg during BB administration), cardiogenic
shock requiring intravenous inotropes (defined as the first
episode of receiving intravenous milrinone, dobutamine or
noradrenaline during BB administration), severe
bronchospasm requiring intravenous steroid (defined as the
first episode of receiving intravenous methylprednisolone
during BB administration), and dose reduction or withdrawal
[defined as the first episode of either receiving a standard dose of
BB that was less than that of the previous day (reduction) or
stopping BB during hospitalization (withdrawal) for any reason].
All patients were followed up throughout the hospitalization. The
survival time of a given time-to-event outcome started on the date
of the initiating BB dose and ended at the occurrence of this
outcome. Patients were considered as censored if they did not
have a given outcome before the earlier date of the last BB dose or
7 days after initiation of BBs.
Statistical Analyses
Descriptive statistics were used for baseline patient
characteristics. The normality of variables was tested using the
Kolmogorov-Smirnov test. Normal continuous variables were
described as mean ± standard deviation (SD) and compared
between groups using the two-sided student’s t-test. Non-normal
continuous variables were shown as median (25% quantile–75%
quantile) and compared using the Mann–Whitney U test.
Categorical variables were reported as frequencies
(percentages) and compared using the Chi-square test.
We adopted inverse probability weighting (IPW) to minimize
the bias due to potential confounders between two groups. (Cole
and Hernán, 2008) We derived propensity score (PS, the
estimated probability of initiating BBs with a dose >1/8 of the
target dose) for each patient using a multivariable logistic
regression model, adjusting for age, sex, baseline heart rate,
baseline systolic BP, baseline NT-proBNP, baseline LVEF,
baseline eGFR, and CCI. We used estimated PSs to calculate
stabilized inverse probability weights which were used in the
following analyses to weight the individual contribution to
models or cumulative probability (Cole and Hernán, 2008).
We presented the effective sample size and the between-group
difference of PS before and after applying IPW. (Supplementary
Figure S1; Supplementary Table S1) Absolute standardized
differences before and after applying IPW were calculated.
(Supplementary Figure S2) The baseline characteristics were
considered comparable if the absolute standardized difference
was less than 0.10. (Supplementary Figure S2).
The IPW-adjusted cumulative incidence was constructed for
all outcomes. A Cox proportional hazards regression model was
used to assess the association of each time-to-event outcome with
guideline non-adherence, weighted by the inverse probability
weights. The proportional hazards assumption was evaluated
by the proportional risk assumption test. The hazard ratios
(HRs) and 95% confidence intervals (CIs) of non-adherence
were reported. For data that did not satisfy the assumption of
proportional hazards (global P < 0.05), we utilized an accelerated
failure time model with Weibull distribution to explore the HR
and 95% CI of the non-adherence group, adjusting for age, sex,
baseline heart rate, baseline systolic BP, baseline NT-proBNP,
baseline LVEF, baseline eGFR, and CCI (Lee and Go, 1997).
Patients were stratified by sex (female/male), age (>/≤60 years
of age), CHD (with/without), and hypertension (with/without)
for subgroup analyses.
We also conducted two sensitivity analyses. The first was to
check whether the results were robust to the addition of
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additional covariates, whether use of CCB, ARB, and venous
furosemide within the two calendar days after admission. The
performance of IPW and absolute standardized differences
between two groups before and after applying IPW were
presented in Supplementary Figures S3, S4. The second
sensitivity analyses adjusted existed covariates, department
of admission (cardiology vs others) and whether the use of
oral thiazide at baseline in the generation of the inverse
probability weights and multivariable accelerated failure
time models. Subgroup analyses included sex, age, status of
hypertension, status of CHD, and individual BB (metoprolol
succinate vs bisoprolol). The performance of IPW and
absolute standardized differences between two groups
before and after applying IPW were presented in
Supplementary Figures S5, S6.
All analyses were conducted using R Studio (R Pack Version
4.1.0, R Core Team, 2021, R Foundation for Statistical
Computing, Vienna, Austria) (R Core Team, 2021), and
figures were produced using the package ggplot2 (Wickham,
2016), survival (Therneau T, 2020), and forestplot (Max
Gordon and Thomas Lumley, 2020). A two-sided P value <
0.05 was considered statistically significant.
FIGURE 1 | Patient disposition.; Abbreviations: WCH, the West China Hospital of Sichuan University; BB, beta blocker; LVEF, left ventricular ejection factor; NT-
proBNP, N-terminal pro-B type natriuretic peptide; LDL-c, low-density lipoprotein; cTNT, cardiac troponin T; HFrEF, heart failure with reduced ejection fraction.
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RESULTS
Guideline Adherence of Initiating BBs in
Hospitalized patients With HFrEF
Among 8,864 patients with LVEF <40%, this study included 1,104
HFrEF inpatients who initiated BBs during hospitalization
(Figure 1). The baseline characteristics of the patients are
shown in Table 1. Among the included patients, 356 (32.2%)
patients were female; 633 (57.3%) patients were aged >60 years;
525 (47.6%) patients had CHD; and 446 (40.4%) patients had
hypertension at baseline. The median length of hospitalization
was 12 days [interquartile range (IQR), 8–17 days].
The clinicians prescribed BB with a higher dose than the
guideline recommendation in 304 (27.5%) patients (median: 1/4
of the target dose). Most patients were initiated BBs within the
first few calendar days of admission (Supplementary Figure S7),
with a higher portion in non-adherent group (Supplementary
Figure S8). Patients in the non-adherence group received more
TABLE 1 | Baseline patient demographic and clinical characteristics.
Variables Overall N = 1,104 Adherence group N = 800
(72.5%)
Non-adherence group N = 304
(27.5%)
P Value
Age, years 61.2 ± 15.2 62.2 ± 14.9 58.6 ± 15.6 <0.001
BMI, kg/m2a 23.0 (20.8, 25.4) 22.8 (20.6, 25.4) 23.3 (21.3, 25.4) 0.41
LVEF (%)a 32.0 (27.0, 36.0) 32.0 (26.0, 36.0) 32.0 (28.0, 36.0) 0.16
Sex, female, n (%) 356 (32.2%) 264 (33.0%) 92 (30.3%) 0.38
Smoking, n (%) 576 (52.2%) 417 (52.1%) 159 (52.3%) 0.96
Alcohol use, n (%) 429 (38.9%) 309 (38.6%) 120 (39.5%) 0.80
CCIa 2.0 (1.0, 3.0) 2.0 (1.0, 3.0) 2.0 (1.0, 3.0) >0.99
Hypertension, n (%) 446 (40.4%) 319 (39.9%) 127 (41.8%) 0.57
Diabetes, n (%) 298 (27.0%) 220 (27.5%) 78 (25.7%) 0.54
CHD, n (%) 525 (47.6%) 408 (51.0%) 117 (38.5%) <0.001
Acute myocardial infarction, n (%) 193 (17.5%) 163 (20.4%) 30 (9.9%) <0.001
Cardiomyopathy, n (%) 393 (35.6%) 285 (35.6%) 108 (35.5%) 0.98
Rheumatic heart disease, n (%) 71 (6.4%) 51 (6.4%) 20 (6.6%) 0.90
Arrhythmia, n (%) 521 (47.2%) 366 (45.8%) 155 (51.0%) 0.12
Death during hospitalization, n (%) 27 (2.4%) 20 (2.5%) 7 (2.3%) 0.85
Admission departments <0.001
Cardiology, n (%) 761 (68.9%) 585 (73.1%) 176 (57.9%)
Cardiac surgery, n (%) 26 (2.4%) 14 (1.8%) 12 (3.9%)
Nephrology, n (%) 22 (2.0%) 10 (1.2%) 12 (3.9%)
Others, n (%) 295 (26.7%) 191 (23.9%) 104 (34.2%)
HR, beats/minutea 88.0 (76.0, 103.0) 89.0 (77.0, 103.0) 85.0 (76.0, 101.2) 0.08
Systolic BP, mmHga 120.0 (105.0, 135.0) 120.0 (104.8, 133.0) 121.0 (108.8, 138.2) 0.03
Diastolic BP, mmHga 76.0 (67.0, 86.0) 75.0 (67.0, 86.0) 78.0 (67.0, 88.0) 0.08
LDL-c, mmol/La 2.2 (1.7, 2.8) 2.2 (1.7, 2.8) 2.3 (1.7, 2.8) 0.42
HbA1c, %a 6.4 (5.9, 7.6) 6.4 (5.9, 7.6) 6.4 (5.8, 7.6) 0.26
eGFR, mL/min·1.73 m2a 71.7 (51.6, 92.0) 70.6 (50.6, 91.3) 74.6 (55.6, 94.9) 0.04
NT-proBNP, pg/mLa 3,996.0 (1,829.8, 8,331.2) 4,198.0 (1,876.0, 9,140.2) 3,506.5 (1,618.2, 6,802.5) 0.01
ALT, mU/La 29.0 (18.0, 54.0) 30.0 (18.0, 55.0) 27.0 (17.0, 48.5) 0.16
Hb, g/La 133.0 (119.0, 146.0) 132.0 (118.0, 146.0) 134.0 (123.0, 146.0) 0.27
CRP, mg/La 10.6 (4.2, 29.5) 11.1 (4.3, 29.1) 10.4 (3.9, 29.6) 0.37
cTnT, ng/La 38.4 (20.7, 143.4) 42.1 (21.3, 198.0) 33.1 (18.9, 74.0) <0.001
Standardized initiating dose, ×target dosea 0.125 (0.0625, 0.25) 0.125 (0.0625, 0.125) 0.25 (0.25, 0.25) <0.001
Individual beta blocker <0.001
Metoprolol succinate, n (%) 789 (71.5%) 638 (79.8%) 151 (49.7%)
Metoprolol tartrate, n (%) 72 (6.5%) 66 (8.2%) 6 (2.0%)
Bisoprolol, n (%) 239 (21.6%) 92 (11.5%) 147 (48.4%)
Others, n (%) 4 (0.4%) 4 (0.5%) 0 (0.0%)
Antihypertensive drugs
ACEI, n (%) 507 (45.9%) 381 (47.6%) 126 (41.4%) 0.07
ARB, n (%) 350 (31.7%) 237 (29.6%) 113 (37.2%) 0.02
CCB, n (%) 219 (19.8%) 141 (17.6%) 78 (25.7%) 0.003
Diuretic
Oral furosemide, n (%) 335 (30.3%) 263 (32.9%) 72 (23.7%) 0.003
Venous furosemide,n (%) 764 (69.2%) 569 (71.1%) 195 (64.1%) 0.03
Oral thiazide, n (%) 212 (19.2%) 139 (17.4%) 73 (24.0%) 0.01
Aldosterone receptor antagonist, n (%) 932 (84.4%) 692 (86.5%) 240 (78.9%) 0.002
aData are presented as median (interquartile range) unless otherwise stated.
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ALT, alanine aminotransferase; Hb, hemoglobin; ARB, angiotensin II, receptor blockers; BMI, bodymass index; NT-proBNP,
N-terminal pro-B-type natriuretic peptide; CCB, calcium channel blocker; CCI, Charlson comorbidity Index; CHD, coronary heart disease; CRP, C-reactive protein; cTnT, cardiac troponin
T; BP, blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HR, heart rate; LDL-c, low-density lipoprotein; LVEF, left ventricular ejection fraction.
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prescriptions of bisoprolol (48.4 vs 11.5%), but less metoprolol
succinate (49.7 vs 79.8%) than the adherence group.
Patients in the non-adherence group were with younger age
(58.6 ± 15.6 years vs 62.2 ± 14.9 years, P < 0.001), less baseline
CHD (38.5 vs 51.0%, P < 0.001), less baseline acute myocardial
infarction (9.9 vs 20.4%, P < 0.001); lower NT-proBNP level
(median, 3,506.5 pg/ml vs 4,198.0 pg/ml; P  0.01); more
prescriptions of ARB or CCB (37.2 vs 29.6%, P  0.02; 25.7 vs
17.6%, P  0.003), and less prescriptions of oral furosemide,
venous furosemide, or aldosterone receptor antagonist (23.7 VS
32.9%, P  0.003; 64.1 vs 71.1%, P  0.03; 78.9 vs 86.5%, P  0.002)
than the adherence group.
Guideline Non-Adherence and Adverse
Events
After applying IPW, baseline characteristics were well balanced
between groups. (Supplementary Figure S2) As shown in
Figure 2, guideline non-adherence was not significantly
associated with a higher risk of profound bradycardia (HR,
1.49; 95% CI, 0.87 to 2.56; P  0.15), hypotension (HR, 1.19;
95% CI, 0.89 to 1.59; P  0.24), cardiogenic shock requiring
intravenous inotropes (HR, 1.11; 95% CI, 0.74 to 1.65; P  0.63),
and severe bronchospasm requiring intravenous steroid (HR,
1.59; 95% CI, 0.90 to 2.80; P  0.11), but was significantly
related to a higher risk of BB dose reduction or withdrawal
(HR, 1.78; 95% CI, 1.42 to 2.22; P < 0.001).
However, we did not find any subgroup effects by age, sex,
with/without CHD, or with/without hypertension on the
association of non-adherence to adverse events (all P
interaction>0.05) (Figure 3).
The first sensitivity analyses showed the results were robust to
the addition of additional covariates, whether use of CCB, ARB,
and venous furosemide within the two calendar days after
admission. (Supplementary Figures S9, S10). The second
sensitivity analyses confirmed the robustness of the results and
did not find any subgroup effect by individual BB.
(Supplementary Figure S11).
DISCUSSION
This is the first study identifying the guideline adherence of BB
initiation in Chinese patients with HFrEF during hospitalization
(Chinese Society of Cardiology of Chinese Medical Association,
2014; Ponikowski et al., 2016). Our study shows that non-
adherence to BB initiating dose was common in real-world
practice. This non-adherent strategy is associated with dose
reduction or withdrawal of the drug, which represents the
intolerance of the drug or fluctuation of the disease. Although
higher dose initiation may not increase the risks of cardiogenic
shock requiring intravenous inotropes or severe bronchospasm
requiring intravenous steroids during hospitalization, initiating
BB adhering to the guideline may fit Chinese patients hospitalized
FIGURE 2 | The IPW-adjusted cumulative incidence of each time-to-event adverse events. We derived propensity score for each patient using a multivariable
logistic regression model, adjusting for age, sex, baseline heart rate, baseline systolic blood pressure, baseline N-terminal pro-B type natriuretic peptide, baseline left
ventricular ejection factor, baseline estimated glomerular filtration rate, and Charlson Comorbidity Index.; Abbreviations: IPW, inverse probability weighting; HR, hazard
ratio; CI, confidence interval. Days are calculated from the date of initiating beta blockers.
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FIGURE 3 | The association between non-adherence to clinical practice guideline recommendations for BB initiation and the risk of adverse events. We derived
propensity score for each patient using a multivariable logistic regression model, adjusting for age, sex, baseline heart rate, baseline systolic blood pressure, baseline
N-terminal pro-B type natriuretic peptide, baseline left ventricular ejection factor, baseline estimated glomerular filtration rate, and Charlson Comorbidity Index. # These
hazard ratios are derived from accelerate failure time model with Weibull distribution; others are derived from Cox proportional hazards regression model with
inverse probability weighting. * The P interaction <0.05. Abbreviations: CI, confidence interval; N, number of patients in each group; n, number of events in each group.
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with HFrEF and enhance the confidence and acceptance of the
drug.
In patients with newly diagnosed HF during hospitalization, BBs
are generally started later than ACEI or ARBs, when the patient is
euvolemic, usually shortly before discharge. Particular caution is
indicated in patients who have required inotropes during their
hospitalization (Ventura, 2004). Our study showed that around a
fourth of the patients in our study received a higher dose of BB than
recommended by clinical practice guidelines and that over a third of
patients reduced or stopped their BBs during hospitalization, which is
not commonly supposed in patients with HFrEF. The dose reduction
or withdrawal represents the intolerance to the drug due to any
reasons, other changes of the patient condition such as worsened
cardiac function or unexpected low heart rate. The specific adverse
outcomes in the studies could be among those reasons of dose
reduction and drug withdrawal of BB, while most causes could
link to unpleasant experience and be unable to identify this study.
Such unpleasure may shift away the confidence and acceptance of BB
use in patients. Such confidence and acceptance are essential to keep
people on the drug after discharge. Furthermore, our findings also
indicated that high-dose initiation may not end up a high discharging
dose of BB due to high rate of dose reduction or discontinuation.
Therefore, the dissemination, implementation and adherence to
guidelines are critical and relevant to everyday patients in practice
and warrants systematic planning and audit (Jin et al., 2021;
Wilkinson et al., 2021).
It is worth noting that this proportion of non-adherence is not
unique to the practice in China as a similar proportion of non-
adherence to guidelines has been reported in primary care in the
United Kingdom (Kalra et al., 2013). Taking both these findings
together, there is an argument that there is a need to monitor this in
wider range of real-world setting. Our study should not dissuade but
rather encourage GPs to uptitrate BBs to their target dose given the
safety and effectiveness of BBs in HFrEF (Fiuzat et al., 2016; Ajam
et al., 2018; Santema et al., 2019). There is an urgent need for a high-
quality long-term management solution for Chinese patients with
HFrEF with plans for up-titration of BBs in their community rather
than the short-term dose achievement of BBs while in hospital
following admission with HF.
Current findings show the extent to which the effects of higher
initiating BB doses than the guideline recommendation was
heterogeneous between sexes, in that the optimal dose of BBs for
the treatment of HFrEFmay be lower for females thanmales, which is
in line with a report by Santema et al. (2019); this difference might be
explained by sex-related differences in pharmacokinetics and
pharmacodynamics (Soldin and Mattison, 2009).
The deduction of our finding was limited for its single-center
nature and lacked a long-term follow-up. It is also worth noting that
there are ethnic differences in responses to BB with previous reports
that the Chinese are more sensitive to BB when compared to
Caucasians (Zhou et al., 1989; Zhou et al., 2021b). It thus needs
external validation in other centers with long-term follow-up and
post-discharge safety outcomes to better understand the clinical
implications of initial higher doses of BBs. Despite adjustment for
several clinical variables, the retrospective study design and
heterogeneous nature of the study populations may have resulted
in unmeasured confounders that were not accounted for in analyses.
Additionally, the dose reduction or withdrawal of BBs represents but
not equals to the intolerance to the drug or any adverse events leading
to discontinuation. Further studies focusing on patient-reported
outcomes such as quality of life and heart failure symptom scores
are necessary to validate the current findings.
CONCLUSION
This study shows that initiating a starting dose of BB that is not
adherent to CPG is common in Chinese patients hospitalized
with HFrEF, which is associated with a higher risk of dose
reduction or withdrawal during hospitalization. Thus, a “start
low, go slow” strategy for BB treatment is appropriate to
minimize drug tolerance, and the guideline adherent audit is
necessary to improve the patients’ outcomes in the real-world
hospital setting.
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